Fig. 2From: FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s diseaseThe antibody response to AADvac1 is immunoglobulin G1-dominated. Values were obtained after the sixth dose of AADvac1Back to article page